Synthetic data is moving from “privacy workaround” to a governed product: new medical evidence favors high-dimensional generation, while policy and research communities focus on bias, drift, and societal impacts.
Impact of synthetic data generation for high-dimensional cross-sectional medical data: fidelity, utility, privacy, and the curse of dimensionality
JAMIA researchers evaluated 12 medical datasets across 7 generative models to test how adding adjunct variables to core task variables changes synthetic data outcomes. Their headline result: generating comprehensive, high-dimensional synthetic datasets better preserves fidelity, utility, and privacy than producing low-dimensional subsets. For health-data platforms, this suggests “minimal variable” synthetic releases can be a false economy if they degrade downstream analysis.
- Data teams should test “wide” synthetic generation paths, not just task-only subsets, when utility is measured on real analytic workflows.
- Privacy reviews should consider that dropping variables doesn’t automatically improve privacy if it harms model fit or induces artifacts.
- Budgeting: high-dimensional synthesis may cost more compute, but can reduce rework and repeated regeneration cycles.
New project to investigate societal consequences of using synthetic data to train algorithms
The ERC-funded SYNDATA project at the University of York, led by Dr. Benjamin Jacobsen, will study the ethical, political, and practical impacts of using synthetic data to train AI across sectors including healthcare and finance. The team plans archival research, fieldwork, and case studies focused on production, representation, and power dynamics. For companies selling synthetic data or synthetic-data tooling, this is a signal that “who benefits, who is represented, and who is harmed” will increasingly show up in procurement and regulation.
- Founders should expect due diligence to expand beyond privacy into provenance, representation, and accountability.
- Compliance leads can use emerging social-science findings to strengthen DPIAs and model risk narratives.
- Product teams may need transparency features (dataset documentation, bias audits) as table stakes.
Synthetic Data: The New Data Frontier
The World Economic Forum briefing paper frames synthetic data as a response to data scarcity, privacy constraints, and testing needs, while flagging risks such as bias amplification. It recommends hybrid approaches, governance, and tailored regulation rather than one-size-fits-all rules. Practically, it reinforces that synthetic data programs need controls: intended use, evaluation metrics, and clear boundaries on when synthetic is acceptable versus when real data access is still required.
- Governance is becoming a differentiator: teams need documented generation methods and validation gates.
- Risk teams should treat bias and “model collapse” concerns as operational issues, not academic footnotes.
NeurIPS 2025 Workshop on AI in the Synthetic Data Age: Challenges and Solutions
Rice University’s DSP announced a NeurIPS 2025 workshop focused on synthetic data in training pipelines, including self-consuming loops that can drive drift, bias reinforcement, and quality degradation. The workshop aims to convene researchers and practitioners around both problems and mitigations. For ML engineers, the key takeaway is to instrument training with lineage and “synthetic ratio” tracking, not just aggregate accuracy.
- Teams training on synthetic should monitor distribution shift and feedback loops across model versions.
- Expect more shared benchmarks and evaluation protocols to emerge from this community focus.
Addressing Bias in Imaging AI to Improve Patient Equity
An RSNA R&E Foundation grant project reports that synthetic data can reduce bias in medical imaging AI by balancing underrepresented datasets, improving fairness and equity in diagnostics. The work positions synthetic augmentation as a practical lever when real-world data is sparse or sensitive. For regulated healthcare AI, this aligns synthetic data with measurable bias mitigation rather than generic “more data” claims.
- Imaging teams can treat synthetic data as a targeted augmentation strategy tied to fairness metrics.
- Documentation of how synthetic examples were generated and validated will matter for audits and regulators.